Waters Corporation Launches New Charge Detection Technology
Waters Corporation (NYSE: WAT) has introduced a groundbreaking advancement in mass spectrometry known as the Xevo Charge Detection Mass Spectrometer (CDMS). This state-of-the-art technology is set to streamline the development of next-generation biotherapeutics by providing unprecedented capabilities in the analysis of large and complex biomolecules.
Unmatched Mass Detection Capabilities
The Xevo CDMS is engineered to facilitate direct and precise mass detection for some of the largest and most heterogeneous biomolecules. This innovative system enables quick and accurate evaluations of protein complexes, nucleic acids, and gene delivery vehicles. Scientists can distinguish between empty, partial, full, and overfull viral vector capsids in under ten minutes per sample, significantly enhancing the analysis process.
Revolutionary Sample Volume Reduction
One of the distinguishing features of the Xevo CDMS is its ability to reduce sample volume by 100-fold compared to current methodologies used for cell and nucleic acid assessments. This capability not only conserves precious sample materials but also accelerates the pace of analysis, allowing researchers to gather data more rapidly and efficiently.
Enhancing Drug Development with Advanced Analytics
Description of the new mass spectrometry tool comes at a time of rapid innovation in therapeutic modalities. The rise of cell and gene therapies, along with mRNA and complex protein therapies, presents significant hurdles for scientists seeking effective analytical methods. Existing tools often fall short of meeting the evolving demands of therapeutics, especially regarding required resolution and sensitivity. The Xevo CDMS addresses these issues by offering direct measurement capabilities for particles up to 150+ MDa in size.
Strategic Vision for the Future
Dr. Udit Batra, President and CEO of Waters, emphasized the strategic importance of strong bioanalytical tools in enhancing therapeutic innovation. He stated, "Today, we proudly introduce the first-of-its-kind Xevo Charge Detection Mass Spectrometer, which will provide essential insights into the characteristics of large molecules that are crucial for bringing transformative therapies to patients in need. This tool represents a leap forward in our commitment to support the next wave of genetic medicine development."
Real-Time Gene Therapy Characterization
The functionality of the Waters Xevo CDMS allows for real-time characterization of gene therapies during the crucial stages of process development. Importantly, this system alleviates the need for complex sample processing methods which are typically required for accurate analysis. By simplifying the analytical workflow, researchers can obtain accurate results that support safety and efficacy studies of novel therapies.
Connecting Science and Innovation
Timothy Fenn, Ph.D., Vice President of Analytical Development at Lexeo Therapeutics, noted the game-changing impact of the CDMS technology. He stated that it enables him and his team to address questions previously deemed unanswerable, thereby enhancing their analytical workflows and yielding reproducible results in a fraction of the time.
Advanced Technology Enables Greater Insights
At the core of the Xevo CDMS is the revolutionary Electrostatic Linear Ion Trap (ELIT) technology, which allows for simultaneous measurement of an ion's mass-to-charge ratio and mass. Developed through a collaborative effort between Indiana University and Megadalton Solutions, this technology significantly enhances the analytical capabilities available to researchers. Following the acquisition of these technologies by Waters in 2022, the company is set to lead in the commercialization of advanced mass spectrometry systems.
About Waters Corporation
For more than 65 years, Waters Corporation (NYSE: WAT) has been at the forefront of innovation in analytical instrumentation, serving a broad array of sectors including life sciences, materials, environmental sciences, and food safety. With its global reach spanning over 100 countries, Waters facilitates the production and quality assurance of medicines, food safety, and environmental analyses through dedicated collaboration with its over 7,600 employees across various industries. The company's commitment to pioneering scientific advancements plays a vital role in enhancing the quality and safety of everyday products.
Frequently Asked Questions
What is the Xevo Charge Detection Mass Spectrometer?
The Xevo Charge Detection Mass Spectrometer is a groundbreaking technology from Waters Corporation, designed to enable precise mass measurement of large biomolecules central to advancing biotherapeutics.
How does the Xevo CDMS improve sample analysis?
It allows for 100-fold menos sample volume compared to existing techniques, providing fast results while maintaining high resolution and sensitivity for complex molecules.
What applications can benefit from this new technology?
The technology supports a wide range of applications from drug discovery and development processes to regulatory approvals in various therapeutic modalities, including gene therapies.
Who developed the core technology behind the Xevo CDMS?
The core technology was developed by distinguished professors at Indiana University, fostering collaboration with Waters for commercialization.
Why is immediate analysis crucial in the development of genetic therapies?
Immediate analysis is vital to ensure safety and efficacy, helping researchers monitor the development of therapies and allowing for timely adjustments to improve outcomes.
